Therapeutic Effects of Modified Mesenchymal Stem Cells Modified by Necrosis of Femoral Head of Rabbit

宫恩年,楼晓,商丰元,魏成刚,施志超,汪劲松,袁丽珍,王立生,郭子宽

DOI: https://doi.org/10.3969/j.issn.1673-0364.2008.03.001

2008-01-01

Abstract:Objective To investigate the osteogenous effect of mesenchymal stem cell and hepatocyte growth factor in the treatment of femoral head osteonecrosis defect. Methods Bone marrow mesenchymal stem cells (MSCs) from New Zealand white rabbit were isolated and culture-expanded by selective adherence to plastic culture flasks and in vitro osteogenesis and adipogenesis ability were identified. Bilateral femoral head osteonecrosis defects in rabbits were surgically established and treated with scaffold of bone matrix gelatin only, or scaffolds seeded with MSCs or MSCs infected by an adenoviral vector carrying human hepatocyte growth factor gene (MSC/HGF). Histological examination was conducted three months post-operation. MSCs or MSC/HGF were labeled with carboxyfluorescein diacetate succinmide ester dye, treated with cobalt chloride for 72 hours and their proliferative status was evaluated and compared by flow cytometric techniques. Results The adherent cells could differentiate into osteoblasts and adipocytes under in vitro inductive conditions. Histological examination revealed that the bone defects from both control and MSCs-treated femoral heads were filled with fibrous tissue, though blood vessels were evident in MSCs group, whereas new bony tissues were obvious in MSC/HGF-treated defects. The results were further confirmed by Lane-Sandhu scaling, which indicated that new bone formation was more evident in MSC/HGF compared with MSCs or control group (p0.01). FCM analysis showed that the proportion of MSC/HGF that had experienced cell division was significantly higher than that of MSCs (p0.001) after cobalt treatment. Conclusion MSC/HGF exhibit greater osteogenesis in vivo in this model compared their counterparts, which might be attributed to their resistance to hypoxic injury. The results suggested that HGF gene modification might be an optional strategy for the application of MSCs in the management of avascular osteonecrosis.